The hyper-CVAD–rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma

Author： Ritchie D.   Seymour J.   Grigg A.   Roberts A.   Hoyt R.   Thompson S.   Szer J.   Prince H.  

Publisher： Springer Publishing Company

ISSN： 0939-5555

Source： Annals of Hematology, Vol.86, Iss.2, 2007-02, pp. : 101-105

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival

By Kim Min   Kim Shin   Lee Sung   Sym Sun   Lee Dae   Jang Seongsoo   Park Chan   Chi Hyun   Huh Jooryung   Suh Cheolwon  

Annals of Hematology, Vol. 86, Iss. 6, 2007-06 ,pp. : 435-442

Springer Publishing Company

Access to resources Recommend Favorite

High-Dose Chemotherapy Followed by Autologous Hematopoietic Stem-Cell Transplantation for the Treatment of Solid Tumors in Adults: A Critical Review

By  

Current Stem Cell Research & Therapy, Vol. 2, Iss. 1, 2007-01 ,pp. : 65-82

Bentham Science Publishers

Access to resources Recommend Favorite

Evaluation of relative anti-myeloma activity of high-dose melphalan followed by the first peripheral blood stem cell transplantation, as compared with the second transplantation, and to VAD chemotherapy

By Awedan A.   Krol M.   Blajer B.   Rokicka M.   Torosian T.   Urbanowska E.   Wiktor-Jedrzejczak W.  

Transplantation Proceedings, Vol. 35, Iss. 6, 2003-09 ,pp. : 2349-2351

Elsevier

Access to resources Recommend Favorite

Feasibility of a dose-adjusted fludarabine-melphalan conditioning prior autologous stem cell transplantation in a dialysis-dependent patient with mantle cell lymphoma

By Tendas Andrea  

Annals of Hematology, Vol. 88, Iss. 3, 2009-03 ,pp. : 285-286

Springer Publishing Company

Access to resources Recommend Favorite

Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma

By Sieniawski Michal   Staak Oliver   Glossmann Jan-Peter   Reineke Thorsten   Scheuß Helena   Diehl Volker   Engert Andreas   Josting Andreas  

Annals of Hematology, Vol. 86, Iss. 2, 2007-02 ,pp. : 107-115

Springer Publishing Company

Access to resources Recommend Favorite